previous Menu

previous

Alpha-fetoprotein (Serum (s))

Specimens:	500 µl Serum (s)
Preanalytics/Notes:	Please state the tentative diagnosis. Patients receiving high doses of biotin (> 5 mg / day) should be sampled at least 8 hours after the last application, as high levels of biotin may interfere with the test system. Please note: results obtained using different methods and/or test manufacturers cannot be compared with one another. The course of tumor markers should always be assessed by the same test.
Method:	ECLIA
Dimension:	IU/ml
Set-up:	Mon Tue Wed Thu Fri Sat Sun
Duration:	1 day
Indication/Significance:	Primary hepatocellular carcinoma Control of patients with liver cirrhosis or chronic hepatitis Germ cell tumour (testicles, ovary, extragonadal) Exclusion of neural tube defect and bifid spine
Interpretation:	Serum AFP values over more… Serum AFP values over 2.5 MoM (borderline normal range: 2.0 - 2.5 MoM) as an indication of neural tube or abdominal wall defects. In accordance with the consensus agreements (Northeim 1997), a specific ultrasonic examination may be recommended and at the patient's request a diagnostic assessment of amniotic fluid (AFP/AChE). Serum AFP values below 0.5 MoM can be an indication of foetal trisomy 21, the diagnostic assessment of which by a further risk analysis (sequential screening test) is also recommended in the Northeim consensus agreements. Evaluation of elevated values: Benign diseases: Liver cirrhosis, acute and chronic hepatitis, haemochromatosis. Patients with liver disease with elevated AFP are subject to a higher risk of developing a hepatocellular carcinoma. Malignant diseases: Primary hepatocellular carcinoma: No correlation between AFP concentration and tumour size, growth and stage. AFP is normal in 5 10 %. Control in patients with liver cirrhosis, germ cell, testicular, ovarian tumours. Other malignant diseases: Rarely elevated with gastric, colon, rectum, biliary tract, pancreatic carcinoma, mostly in connection with liver metastases. close
Further tests:	According to the Consensus Agreements (Northeim 1997), a targeted ultrasound examination is recommended, and a clarification from fruit water (AFP / ACHE) is recommended at the request of the patient. Serum AFP values ¿¿below 0.5 MoM may be indicative of a fetal trisomy 21, which is also recommended in the Northeimer Consensus Agreements by a further screening study (Sequential Screening).

Reference range / valuation (openclose)

male
0 Days	< 42000,0 IU/ml
from 1 Day - 0 Months	< 13600,0 IU/ml
from 1 Month - 11 Months	< 23,0 IU/ml
from 12 Months - 2 Years	< 6,6 IU/ml
from 3 Years - 5 Years	< 4,6 IU/ml
from 6 Years - 11 Years	< 3,1 IU/ml
from 12 Years - 17 Years	< 3,2 IU/ml
from 18 Years - 120 Years	< 5,8 IU/ml

female
0 Days	< 42000,0 IU/ml
from 1 Day - 0 Months	< 15700,0 IU/ml
from 1 Month - 11 Months	< 64,0 IU/ml
from 12 Months - 2 Years	< 9,2 IU/ml
from 3 Years - 5 Years	< 3,5 IU/ml
from 6 Years - 11 Years	< 4,6 IU/ml
from 12 Years - 17 Years	< 3,5 IU/ml
from 18 Years - 120 Years	< 5,8 IU/ml

Representation of age: "from" refers to the commenced year(s) (month) of age; "until" refers to the completed year(s) (month) of age.

initial letter

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Close

Abrechnung GOÄ

Die Kosten werden für den i. d. R. genutzten 1,15-fachen GOÄ-Satz dargestellt. Wird die Untersuchung nicht in Ihrem regionalen Labor durchgeführt, erfolgt die Analyse in dem Labor, das im Leistungsverzeichnis genannt ist. In diesem Fall gilt der dort für die Untersuchung angegebene Preis.